TheraRadar
Landscape / Oncology
Page updated Jul 4, 2026 · using data updated on Jun 28, 2026

Melanoma Clinical Trial Landscape

Melanoma is a type of skin cancer that develops from melanocytes, the cells that produce melanin. While it can occur anywhere on the body, it most often affects skin that has been exposed to the sun.

The clinical trial landscape for melanoma is robust, with 1,633 trials registered since 2008, and 515 currently active. Activity is heavily concentrated in early-phase trials, with 256 active Phase 1 and 312 active Phase 2 trials, compared to 59 active Phase 3 and 8 active Phase 4 trials.

Several industry sponsors are actively involved in melanoma research. Merck, Bristol-Myers Squibb, Novartis, and Regeneron are each sponsoring 6 or 7 active trials, and Iovance Biotherapeutics, Inc. is also sponsoring 6 active trials.

The high volume of Phase 1 and 2 trials suggests a strong focus on novel therapeutic approaches and early-stage drug development in this indication.

Trial activity

521 active / 1,655 total since 2008
Active by phase 60 Ph3 / 138 306 Ph2 / 932 146 Ph1 / 564 9 Ph4 / 21

Competitive Intelligence

This Melanoma competitive landscape maps 7 companies against 9 mechanisms of action (MOA) across 9 active drug-development programs, including 1 with a confirmed FDA PDUFA date. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in Melanoma, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

Beta 7 companies 9 mechanisms 9 programs mapped 2 lowTrust (22%) 1 ⚖ PDUFA-dated ⏰ 3 due ≤6 mo click any cell → asset tearsheet
At a glance

Melanoma shows 9 programs across 7 companies and 9 mechanisms. The most contested mechanism is LAG-3 (3 programs).

Key findings
  • Top 3 mechanisms (TIL therapy, CTLA-4 / LAG-3, LAG-3) account for ~13% of programs — class concentration is low.
  • Regeneron runs 5 programs — the deepest pipeline in this view.
  • HUYABIO International, LLC. has the highest composite score (100) — most-imminent / most-advanced asset weighted higher than program count.
  • 13 hot readouts in next 6 months — most imminent: Iovance Biotherapeutics (TIL therapy).
  • 14 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
  • 43 single-program mechanisms in the long tail — 5 are Ph2+ first-in-class first-mover bets.
  • 33 NME candidates in the long tail.
  • Most-novel-of-novel: Philogen S.p.A. TNF (Ph3) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 3 due ≤6 mo⚖ 1 PDUFA-dated

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet.
Unverified (lowTrust) cells:
Ph1 Ph2 Ph3 Ph4 ⚠ lowTrust +combo
Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →
LAG-3
TIL therapy
PD-1 (cemiplimab)
Personalized neoantigen mRNA canc…
PD-1 (pembrolizumab)
CTLA-4 / LAG-3
PKC
Oncolytic adenovirus (TNFα/IL-2 a…
BRAF / MEK
Regeneron
Merck & Co.
Iovance Biotherapeutics
Bristol-Myers Squibb
IDEAYA
TILT Biotherapeutics
Pierre Fabre Medicament

Phase 3 leaders · most advanced

  1. active National Cancer Institute (NCI) NCT02339571
  2. recruiting Canadian Cancer Trials Group NCT02821013
  3. recruiting Eikon Therapeutics NCT06697301
  4. recruiting IDEAYA Biosciences NCT07015190
  5. recruiting Regeneron Pharmaceuticals NCT06246916

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 9 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.
⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes
Single-program mechanisms (43) — one program each — earliest-stage, sorted by phase
PhaseMechanismCompanyModalityReadoutTrial
Ph3 IL-2 immunocytokine 🌱 🆕 ⚙️ Philogen S.p.A. 4Q27 NCT03567889
Ph3 MEK inhibitor 🌱 🆕 Shanghai Kechow Pharma IV 3Q27 NCT06008106
Ph3 Oncolytic virus 🌱 🆕 ⚙️ Binhui Biopharmaceutical 1Q26 NCT05868707
Ph3 PD-1 × CTLA-4 bispecific 🌱 🆕 ⚙️ Biocad ⏰ 1Q27 NCT05751928
Ph3 Photoimmunotherapy (uveal melanoma) 🌱 🆕 Aura 4Q27 NCT06007690
Ph2+Ph3 ROS1 / ALK 🌱 IDEAYA IV 1Q27 NCT05987332
Ph3 TCR-bispecific (gp100) ⚡ 🌱 Immunocore Cell therapy 1Q28 NCT05549297
Ph2+Ph3 TLR7/8 agonist 🌱 🆕 Eikon IV 4Q35 NCT06697301
Ph3 TNF ⚡ 🌱 🆕 Philogen S.p.A. 4Q24 NCT02938299
Ph2 (TLR7 agonist 🌱 🆕 Primmune IV 4Q27 NCT07565285
Ph2 Autologous T-cell (TIL) ⚡ 🌱 ⚙️ Shanghai Juncell IV ⏰ 3Q26 NCT06703398
Ph2 B7-H3 ADC 🌱 🆕 Daiichi Sankyo 3Q28 NCT06330064
Ph1+Ph2 CD47 / SIRPα 🌱 🆕 ⚙️ Zhuhai Yufan 2Q25 NCT06727630
Ph2 CTLA-4 (Fc-enhanced) 🌱 🆕 Agenus IV 1Q28 NCT05529316
Ph1+Ph2 FAK inhibitor 🌱 🆕 Hangzhou Hanx Biopharmace… 4Q27 NCT06708663
Ph1+Ph2 IFNAR ⚡ 🌱 Diakonos Oncology Corpora… 1Q31 NCT07288112
Ph1+Ph2 IL-15 agonist (cytoTIL) 🌱 🆕 ⚙️ Obsidian 2Q29 NCT06060613
Ph1+Ph2 MDM2 🌱 Ascentage Pharma Group IV 4Q25 NCT03611868
Ph2 MTAP / PRMT5 🌱 Bristol-Myers Squibb IV 2Q32 NCT07492680
Ph2 MTOR 🌱 🆕 Rapa Cell therapy 1Q29 NCT06708455
Ph1+Ph2 Oncolytic HSV-1 (anti-PD-1 armed) 🌱 🆕 Shanghai Pharmaceuticals … ⏰ 3Q26 NCT06214156
Ph1+Ph2 ORNITHINE DECARBOXYLASE 🌱 Aminex IV 1Q28 NCT07287917
Ph1+Ph2 OX40 🌱 🆕 BeiGene IV 2Q25 NCT05661955
Ph1+Ph2 PD-1 (Hanzhong) 🌱 🆕 Binhui Biopharmaceutical 4Q25 NCT04616443
Ph2 PD-1 × IL-2 bispecific 🌱 🆕 ⚙️ Innovent Biologics (Suzho… 2Q25 NCT06081920
Ph1+Ph2 PD-1 gene-edited TIL therapy 🌱 🆕 ⚙️ Iovance Biotherapeutics 3Q27 NCT05361174
Ph2 PD-L1 / VEGF-A bispecific antibody 🌱 🆕 DualityBio 2Q30 NCT06953089
Ph2 PI3K inhibitor 🌱 🆕 iOnctura 4Q27 NCT06717126
Ph1+Ph2 PMEL17 (gp100) ADC 🌱 🆕 Novartis 4Q27 NCT05415072
Ph2 RAF 🌱 Novartis Oral 1Q27 NCT04417621
Ph1+Ph2 RIPK2 inhibitor ⚡ 🌱 🆕 ⚙️ Oncodesign Precision Medi… 3Q27 NCT07040436
Ph1+Ph2 T CELL RECEPTOR 🌱 🆕 Marengo ⏰ 4Q26 NCT05592626
Ph2 TIL therapy (BlueHorse) 🌱 Suzhou BlueHorse IV 4Q27 NCT07310784
Ph2 Wnt pathway inhibitor 🌱 🆕 ⚙️ DermBiont 4Q24 NCT06409195
Ph1 BRAF 🌱 🆕 Pierre Fabre Medicament Oral 4Q28 NCT04913285
Ph1 CXCR1/2 🌱 🆕 Syntrix Biosystems IV ⏰ 3Q26 NCT03161431
Ph1 DLK1 🌱 🆕 Chiome Bioscience 2Q27 NCT06636435
Ph1 IL-2 variant ⚡ 🌱 🆕 ⚙️ Qingdao Sino-Cell Biomedi… ⏰ 2Q26 NCT06941818
Ph1 MAGE-A1 (HLA-A*02:01 TCR-T) 🌱 🆕 TScan ⏰ 4Q26 NCT05973487
Ph1 PD-1 inhibitor (pembrolizumab biosimilar) 🌱 🆕 Shanghai Henlius IV 2Q27 NCT07160335
Ph1 Peptidoglycan inhibitor ⚡ 🌱 Microbiotica IV 4Q25 NCT06540391
Ph1 T-CELL RECEPTOR ⚡ 🌱 🆕 Guangzhou FineImmune 2Q27 NCT06942143
Ph1 TIM-3 inhibitor 🌱 🆕 GSK IV 1Q27 NCT02817633
Emerging & small-cap sponsors (13) — few programs here — partnering / M&A radar
PhaseMechanismCompanyModalityReadoutTrial
Ph1 Radioligand (isotope-labeled) Alpha-9 Oncology USA 1Q28 NCT07076550
Ph1+Ph2 🇨🇳 BRAF inhibitor Beijing Scitech-Mq Pharma… ⏰ 4Q26 NCT06359860
Ph1 Radioligand (isotope-labeled) Boehringer Ingelheim ⏰ 3Q26 NCT05068102
Ph1 Undisclosed target Conjupro Biotherapeutics 3Q29 NCT07317505
Ph2 BRAF inhibitor Hanmi Pharmaceutical Comp… Oral 3Q29 NCT07449754
Ph3 PD-1 (nivolumab) HUYABIO International, LL… IV ⏰ 3Q26 NCT04674683
Ph3 TIL therapy Immatics US Cell therapy 1Q28 NCT06743126
Ph1+Ph2 CTLA-4 / LAG-3 Krystal IV 3Q27 NCT05970497
Ph3 PD-1 (nivolumab) mAbxience Research S.L. IV 2Q27 NCT07221734
Ph2 Personalized neoantigen mRNA cancer vaccine ModernaTX IM 4Q32 NCT03897881
Ph1 Radioligand (isotope-labeled) Modulation 1Q27 NCT05496686
Ph3 BRAF / MEK Pfizer IV 1Q26 NCT04657991
Ph1+Ph2 🇨🇳 Undisclosed target Shanghai JMT-Bio ⏰ 4Q26 NCT07280832
Unclassified programs (50) — mechanism not captured yet
PhaseMechanismCompanyModalityReadoutTrial
Ph2+Ph3 LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomi…unclassified Linnaeus Therapeutics, In… NCT06624644
Ph2+Ph3 RP2, Ipilimumab, Nivolumabunclassified Replimune, Inc. NCT06581406
Ph3 Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimabunclassified Replimune, Inc. NCT06264180
Ph3 Naporafenib, Dacarbazine, Temozolomideunclassified Erasca, Inc. NCT06346067
Ph3 Brenetafusp, Nivolumab, Nivolumab + Relatlimabunclassified Immunocore Ltd NCT06112314
Ph3 ABP 206, Nivolumabunclassified Amgen NCT06054555
Ph3 IO102-IO103, Pembrolizumabunclassified IO Biotech NCT05155254
Ph3 BCD-263, Opdivounclassified Biocad NCT06640530
Ph1+Ph2 IMA203 Product, IMA203 product- flat dose, IMA203CD8 Productunclassified Immatics US, Inc. NCT03686124
Ph1+Ph2 TRK-950, TRK-950, TRK-950unclassified Toray Industries, Inc NCT05423262
Ph1+Ph2 GIM-531, Anti-PD-1 monoclonal antibodyunclassified Georgiamune Inc NCT06425926
Ph1+Ph2 [203Pb]VMT01, [212Pb]VMT01, Nivolumabunclassified Perspective Therapeutics NCT05655312
Ph1+Ph2 BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injec…unclassified BioInvent International AB NCT04752826
Ph2 RP1, nivolumabunclassified Replimune, Inc. NCT03767348
Ph2 Lymphodepletion Conditioning, Infusion of HS-IT101 Injection, I…unclassified Qingdao Sino-Cell Biomedi… NCT07406724
Ph1+Ph2 IDE196, Binimetinib, Crizotinibunclassified IDEAYA Biosciences NCT03947385
Ph2 SCIB1 or iSCIB1+ DNA vaccineunclassified Scancell Ltd NCT04079166
Ph1+Ph2 LNS8801 -Small molecule, orally bioavailable, selective agonist…unclassified Linnaeus Therapeutics, In… NCT04130516
Ph1+Ph2 LBL-024 for Injection, LBL-007 Injection, Toripalimab Injectionunclassified Nanjing Leads Biolabs Co.… NCT07099430
Ph1+Ph2 IOV-3001unclassified Iovance Biotherapeutics, … NCT06940739
Ph1+Ph2 NBM-BMX Capsule are proprietary products developed by Novelwise…unclassified Novelwise Pharmaceutical … NCT07136181
Ph1+Ph2 pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg…unclassified BioInvent International AB NCT06784648
Ph2 EVX-01, Pembrolizumab 25 MG/MLunclassified Evaxion Biotech A/S NCT05309421
Ph1+Ph2 OH2 injection, Keytrudaunclassified Binhui Biopharmaceutical … NCT04386967
Ph1+Ph2 BA3071, Nivolumab, Pembrolizumabunclassified BioAtla, Inc. NCT05180799
Ph2 IBI363, Pembrolizumabunclassified Innovent Biologics (Suzho… NCT06797297
Ph2 VV1, Cemiplimabunclassified Vyriad, Inc. NCT04291105
Ph2 L19IL2, L19TNF, L19IL2/L19TNFunclassified Philogen S.p.A. NCT06284590
Ph1+Ph2 ENB003, Pembrolizumabunclassified ENB Therapeutics, Inc NCT04205227
Ph2 TQB2916 injection + doxorubicin hydrochloride for injection, TQ…unclassified Chia Tai Tianqing Pharmac… NCT06500091
Ph1+Ph2 EOS-448, pembrolizumab, inupadenantunclassified iTeos Belgium SA NCT05060432
Ph2 IO102-IO103, Pembrolizumab KEYTRUDA®unclassified IO Biotech NCT05280314
Ph1+Ph2 EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Flud…unclassified Beijing Biotech NCT07627698
Ph2 methoxsalen, Vedolizumab, Infliximabunclassified Therakos LLC NCT07619898
Ph1 RLY-8161unclassified Relay Therapeutics, Inc. NCT07584226
Ph1 Bmab1800, US-Licensed Keytrudaunclassified Biocon Biologics UK PLC NCT07581509
Ph1 GME751, Keytruda - EU, Keytruda - USunclassified Sandoz NCT06153238
Ph1 PF-08046033unclassified Pfizer NCT07519655
Ph1 BI 3810944unclassified Boehringer Ingelheim NCT07224425
Ph1 HLX18, OPDIVO®unclassified Shanghai Henlius Biotech NCT07518043
Ph1 Bmab1700, Opdivounclassified Biocon Biologics UK PLC NCT07476326
Ph1 Belvarafenib, Cobimetinib, Nivolumabunclassified Genentech, Inc. NCT04835805
Ph1 AVT32-DRL_PB, Keytrudaunclassified Alvotech Swiss AG NCT07475572
Ph1 PH-762unclassified Phio Pharmaceuticals Inc. NCT06014086
Ph1 X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breas…unclassified Immunolight, LLC NCT04389281
Ph1 IMA203, mRNA-4203unclassified Immatics US, Inc. NCT06946225
Ph1 Adze1.Cunclassified Adze Biotechnology Austra… NCT07086105
Ph1 FYB206, Keytrudaunclassified Formycon AG NCT06551064
Ph1 R-5780unclassified Rise Therapeutics LLC NCT06398418
Ph1 KUP-101Aunclassified Kupando GmbH NCT07600476
Drugs in this landscape: cemiplimab · Lifileucel plus Pembrolizumab · Pembrolizumab · Nivolumab + Relatlimab · Encorafenib and Binimetinib

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
Bristol-Myers Squibb 6 39 11
Merck 6 19 3
Novartis 6 14 8
Regeneron 6 3 2
Iovance Biotherapeutics, Inc. 5 1 1
Roche 4 36 5
Pfizer 4 8 14
Biocad 4 1 0
IDEAYA Biosciences 4 0 0
Philogen S.p.A. 3 4 1
Innovent Biologics (Suzhou) Co. Ltd. 3 0 2
Replimune, Inc. 3 0 0
Binhui Biopharmaceutical Co., Ltd. 3 0 0
AstraZeneca 2 5 0
Immunocore Ltd 2 3 2

All 15 active Melanoma sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2021 (112 registered); 2025 saw 97. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (85 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
94
2017
84
2018
102
2019
87
2020
87
2021
112
2022
103
2023
90
2024
74
2025
97
2026
58

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (7)
214
2017 (8)
480
2018 (8)
517
2019 (4)
418
2020 (4)
255
2021 (7)
257
2022 (9)
407
2023 (16)
416
2024 (11)
290
2025 (9)
360
2026 (2)
387

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT02339571 ACTIVE NOT RECRUITING
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI) n=600
NCT02821013 RECRUITING
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Canadian Cancer Trials Group n=614
NCT06697301 RECRUITING
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Eikon Therapeutics n=740
NCT07015190 RECRUITING
Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences n=520
NCT06246916 RECRUITING
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals n=560
NCT01274338 ACTIVE NOT RECRUITING
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI) n=1,673
NCT02506153 ACTIVE NOT RECRUITING
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI) n=1,301
NCT06500455 RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology n=269
NCT05522660 RECRUITING
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation n=180
NCT07552597 NOT YET RECRUITING
Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II
Vastra Gotaland Region n=254
NCT06624644 RECRUITING
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc. n=135
NCT05352672 ACTIVE NOT RECRUITING
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Regeneron Pharmaceuticals n=1,546
NCT06743126 RECRUITING
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Immatics US, Inc. n=360
NCT07530887 RECRUITING
NO Re-excision MelanomA - NORMA 2
Marieke Goodijk n=1,749
NCT04099251 ACTIVE NOT RECRUITING
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Bristol-Myers Squibb n=790
NCT04657991 ACTIVE NOT RECRUITING
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer n=257
NCT05727904 RECRUITING
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc. n=670
NCT06581406 RECRUITING
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc. n=280
NCT06264180 RECRUITING
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Replimune, Inc. n=400
NCT06488482 RECRUITING
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
Uppsala University n=1,792
NCT02362594 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Merck Sharp & Dohme LLC n=1,019
NCT06246149 RECRUITING
Adjuvant Tebentafusp in High Risk Ocular Melanoma
European Organisation for Research and Treatment of Cancer - EORTC n=290
NCT06007690 RECRUITING
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Aura Biosciences n=100
NCT06346067 ACTIVE NOT RECRUITING
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc. n=78
NCT05549297 RECRUITING
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Immunocore Ltd n=540
NCT06112314 RECRUITING
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Immunocore Ltd n=680
NCT02224781 ACTIVE NOT RECRUITING
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
National Cancer Institute (NCI) n=267
NCT05987332 ACTIVE NOT RECRUITING
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
IDEAYA Biosciences n=420
NCT07221734 RECRUITING
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
mAbxience Research S.L. n=632
NCT06054555 ACTIVE NOT RECRUITING
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Amgen n=633
NCT07310758 RECRUITING
Contrast-enhanced Ultrasound for Sentinel Node Detection
The Netherlands Cancer Institute n=91
NCT03567889 RECRUITING
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Philogen S.p.A. n=186
NCT06794775 RECRUITING
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
Hildur Helgadottir n=128
NCT05770544 RECRUITING
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Cancer Research UK n=30
NCT05768178 RECRUITING
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK n=30
NCT05770102 RECRUITING
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Cancer Research UK n=30
NCT07068074 NOT YET RECRUITING
A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients
Eastern Cooperative Oncology Group n=428
NCT01223248 ACTIVE NOT RECRUITING
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Memorial Sloan Kettering Cancer Center n=220
NCT05933577 ACTIVE NOT RECRUITING
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Merck Sharp & Dohme LLC n=1,089
NCT04674683 ACTIVE NOT RECRUITING
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
HUYABIO International, LLC. n=450
NCT03470922 ACTIVE NOT RECRUITING
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Bristol-Myers Squibb n=714
NCT05155254 ACTIVE NOT RECRUITING
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
IO Biotech n=407
NCT05625399 ACTIVE NOT RECRUITING
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Bristol-Myers Squibb n=579
NCT05868707 RECRUITING
OH2 Injection in Melanoma
Binhui Biopharmaceutical Co., Ltd. n=340
NCT06640530 ACTIVE NOT RECRUITING
Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Biocad n=392
NCT05751928 ACTIVE NOT RECRUITING
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
Biocad n=411
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT05502900 RECRUITING
Adjuvant Melatonin for Uveal Melanoma
Gustav Stalhammar n=100
NCT05608291 ACTIVE NOT RECRUITING
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals n=1,564
NCT05899465 RECRUITING
Perioperative Treatment With Tranexamic Acid in Melanoma
University of Aarhus n=1,204
NCT05732805 ACTIVE NOT RECRUITING
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Biocad n=270
NCT03553836 ACTIVE NOT RECRUITING
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Merck Sharp & Dohme LLC n=976
NCT06519266 RECRUITING
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases
Vastra Gotaland Region n=40
NCT02938299 ACTIVE NOT RECRUITING
Neoadjuvant L19IL2/L19TNF- Pivotal Study
Philogen S.p.A. n=214
NCT06008106 RECRUITING
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Shanghai Kechow Pharma, Inc. n=165
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT04309409 ACTIVE NOT RECRUITING
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
University Hospital, Essen n=374
NCT04949113 ACTIVE NOT RECRUITING
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
The Netherlands Cancer Institute n=423
NCT05270044 ACTIVE NOT RECRUITING
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Pierre Fabre Medicament n=815
NCT05789043 RECRUITING
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
Peking University Cancer Hospital & Institute n=140
NCT01682083 COMPLETED
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
Novartis Pharmaceuticals n=870
NCT05907122 COMPLETED
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen n=256
NCT01909453 COMPLETED
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Pfizer n=921
NCT06587451 TERMINATED
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Sandoz n=52
NCT03820986 COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
Merck Sharp & Dohme LLC n=674
NCT01983748 COMPLETED
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
University Hospital Erlangen n=200
NCT05002569 TERMINATED
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Bristol-Myers Squibb n=1,093
NCT04889118 COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
Merck Sharp & Dohme LLC n=131
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT01546571 TERMINATED
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Polynoma LLC n=504
NCT05665595 COMPLETED
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Merck Sharp & Dohme LLC n=1,594
NCT01861938 WITHDRAWN
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Hadassah Medical Organization
NCT02967692 TERMINATED
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Novartis Pharmaceuticals n=568
NCT04695977 TERMINATED
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals n=20
NCT02752074 COMPLETED
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Incyte Corporation n=706
NCT02908672 COMPLETED
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche n=514
NCT04588246 TERMINATED
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology n=19
NCT01844505 COMPLETED
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Bristol-Myers Squibb n=945
NCT02166788 COMPLETED
Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma
Melanoma and Skin Cancer Trials Limited n=634
NCT03551626 COMPLETED
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
Novartis Pharmaceuticals n=552
NCT02388906 COMPLETED
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
Bristol-Myers Squibb n=906
NCT03635983 COMPLETED
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Bristol-Myers Squibb n=783
NCT03172299 COMPLETED
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
Centre Hospitalier Universitaire de Nice n=57
NCT02278887 COMPLETED
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
The Netherlands Cancer Institute n=168
NCT04901988 TERMINATED
Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION
The Christie NHS Foundation Trust n=8
NCT05297565 COMPLETED
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
Bristol-Myers Squibb n=14
NCT01748448 COMPLETED
Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
Universitaire Ziekenhuizen KU Leuven n=436
NCT02993315 COMPLETED
Melanoma Patients Immunized with Natural DenDritic Cells
Radboud University Medical Center n=148
NCT03430297 COMPLETED
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
Shanghai Junshi Bioscience Co., Ltd. n=256
NCT03233828 TERMINATED
Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2
Carman Giacomantonio n=1
NCT01785316 COMPLETED
The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
Vastra Gotaland Region n=93
NCT02678572 COMPLETED
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Delcath Systems Inc. n=102
NCT04410445 TERMINATED
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Nektar Therapeutics n=765
NCT04277663 TERMINATED
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
Innovent Biologics (Suzhou) Co. Ltd. n=136
NCT03928275 WITHDRAWN
The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma
Carman Giacomantonio
NCT03294330 COMPLETED
SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
Milton S. Hershey Medical Center n=35
NCT02997553 COMPLETED
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
Institut de Cancérologie de Lorraine n=744
NCT01720407 COMPLETED
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Nantes University Hospital n=259
NCT02263508 TERMINATED
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Amgen n=713
NCT03445533 TERMINATED
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc. n=481
NCT03273153 TERMINATED
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Hoffmann-La Roche n=446
NCT02843386 COMPLETED
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
Institut Curie n=302
NCT01721772 COMPLETED
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
Bristol-Myers Squibb n=418
NCT02714218 COMPLETED
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Bristol-Myers Squibb n=387
NCT01689519 COMPLETED
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
Hoffmann-La Roche n=495
NCT01721746 COMPLETED
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Bristol-Myers Squibb n=405
NCT02288897 TERMINATED
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Biopharmaceuticals, Inc. n=20
NCT03068455 COMPLETED
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
Bristol-Myers Squibb n=1,844
NCT03329846 COMPLETED
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
Bristol-Myers Squibb n=20
NCT02599402 COMPLETED
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Bristol-Myers Squibb n=533
NCT01763164 COMPLETED
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer n=402
NCT00796445 TERMINATED
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
GlaxoSmithKline n=1,351
NCT01597908 COMPLETED
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Novartis Pharmaceuticals n=704
NCT01584648 COMPLETED
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Novartis Pharmaceuticals n=423
NCT02905266 COMPLETED
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
Bristol-Myers Squibb n=106
NCT01280565 TERMINATED
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
AB Science n=134
NCT01826864 WITHDRAWN
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Jonsson Comprehensive Cancer Center
NCT01866319 COMPLETED
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Merck Sharp & Dohme LLC n=834
NCT02545075 COMPLETED
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
Bristol-Myers Squibb n=182
NCT00636168 COMPLETED
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Bristol-Myers Squibb n=1,211
NCT00864253 COMPLETED
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Celgene n=529
NCT01515189 COMPLETED
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
Bristol-Myers Squibb n=831
NCT01667419 COMPLETED
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
Hoffmann-La Roche n=498
NCT01875653 TERMINATED
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Lisata Therapeutics, Inc. n=4
NCT00540969 TERMINATED
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases
Alliance for Clinical Trials in Oncology n=3
NCT01006252 TERMINATED
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
Eli Lilly and Company n=336
NCT01245062 COMPLETED
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
GlaxoSmithKline n=322
NCT01264874 TERMINATED
MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients
European Institute of Oncology n=150
NCT01307397 COMPLETED
A Study of Vemurafenib in Participants With Metastatic Melanoma
Hoffmann-La Roche n=3,219
NCT01974752 COMPLETED
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
AstraZeneca n=152
NCT02427893 WITHDRAWN
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01006980 COMPLETED
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Hoffmann-La Roche n=675
NCT00769704 COMPLETED
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
BioVex Limited n=437
NCT01368276 COMPLETED
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
BioVex Limited n=31
NCT00671918 COMPLETED
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Navidea Biopharmaceuticals n=186
NCT01106040 COMPLETED
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Navidea Biopharmaceuticals n=163
NCT01013623 TERMINATED
Stage IV Surgery Versus Best Medical Therapy
Saint John's Cancer Institute n=12
NCT01272609 TERMINATED
Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel
Centre Hospitalier Universitaire de Nice n=25

Full Melanoma Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the Melanoma landscape

How many companies are developing Melanoma treatments?
7 companies have active or registered Melanoma programs in TheraRadar's competitive landscape (75 classified trials). The most active are Regeneron, Merck & Co., and Iovance Biotherapeutics.
What mechanisms of action are being developed for Melanoma?
9 distinct mechanisms of action appear across the Melanoma pipeline, including LAG-3, TIL therapy, PD-1 (cemiplimab), Personalized neoantigen mRNA cancer vaccine, and PD-1 (pembrolizumab).
What is the most crowded mechanism in Melanoma?
LAG-3 is the most contested mechanism in Melanoma, with 3 programs mapped to it.
Are there upcoming Melanoma clinical readouts or FDA decisions?
Near-term Melanoma catalysts include Pembrolizumab (FDA decision, Aug '26); TILT-123 (data readout, Nov '26); cemiplimab (data readout, Nov '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Melanoma landscape data come from?
Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Melanoma heatmap free to use?
Yes — viewing and searching the Melanoma heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.
How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

  • In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
  • Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

  1. Healthy-volunteer studies are set aside as non-disease trials.
  2. Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
  3. Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
  4. Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
  5. Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

  1. Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
  2. Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
  3. Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
  4. AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

  • ✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
  • ⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
  • ⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
  • 🌱 First-in-indication — the only program competing on that mechanism within this disease.
  • 🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
  • 🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

  • Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
  • Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
  • Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

  • Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
  • Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
  • MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
  • Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

  • First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
  • NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
  • Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
  • AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
  • Sponsor names are as-filed and may lag current ownership.
  • Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only